Moreau P, Mateos MV, Berenson JR, et al. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed, refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol. 2018, 19(7):953-964. doi: 10.1016/S1470-2045(18)30354-1.
Advertisement
Articles by Moreau P, Mateos MV, Berenson JR, et al. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed, refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol. 2018, 19(7):953-964. doi: 10.1016/S1470-2045(18)30354-1.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Moderna, Merck mRNA Cancer Vaccine Succeeds in Late-Stage Trial
2
County-Level CRC Mortality Disparities Linked to Broadband Gaps, Smoking, and Rurality
3
Monitoring Disease Progression and Liver Cancer Risk in Hepatitis B
4
Quantitative HBsAg Testing and the Path to Finite-Duration Therapy
5